Application of Anlotinib Combined With Neoadjuvant Chemotherapy in Primary EWS/PNET of Lung: A Case Report

Application of Anlotinib Combined With Neoadjuvant Chemotherapy in Primary EWS/PNET of Lung: A Case Report

Primary pulmonary EWS/PNET(PPES) is extremely rare and is associated with a poor prognosis. Tumor angiogenesis plays an important role in tumor, so it has become a hot topic in molecular targeted therapy. Anlotinib is a new oral small molecular multi-targeted receptor tyrosine kinase (RTK) inhibitor...

Full description

Bibliographic Details
Main Authors:	YH Fan, HX Ma, SP Guo, Y Chen, SP Zhang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-04-01
Series:	Frontiers in Oncology
Subjects:	ewing’s Sarcoma pulmonary Anlotinib Neoadjuvant chemotherapy multi-targeted receptor tyrosine kinase
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.822469/full

Similar Items

Primary EWS/PNET of the lung with TP53 germline and SKT11 somatic mutation: A case report and review of the literature
by: Shuangping Zhang, et al.
Published: (2022-01-01)

Subungual Ewing sarcoma/PNET tumor family of the great toe: a case report
by: Fariba Binesh, et al.
Published: (2016-04-01)

Case Report: Successful Treatment of Kaposi’s Sarcoma With Anlotinib in an HIV-Negative Patient After the Treatment of Drug Reaction With Eosinophilia and Systemic Symptoms Accessory Tragus
by: Min Lin, et al.
Published: (2022-05-01)

The Activity and Safety of Anlotinib for Patients with Extremity Desmoid Fibromatosis: A Retrospective Study in a Single Institution
by: Zheng C, et al.
Published: (2020-09-01)

A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer
by: Jia-Yi Huang, et al.
Published: (2023-04-01)

Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas
by: Víctor Albarrán, et al.
Published: (2022-11-01)

Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
by: Guoshuang Shen, et al.
Published: (2018-09-01)

Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma
by: Zhi‐Ming Wang, et al.
Published: (2020-05-01)

Durable efficacy of anlotinib in a patient with advanced thymic squamous cell carcinoma after multiline chemotherapy and apatinib: A case report and literature review
by: Ran Zuo, et al.
Published: (2020-11-01)

Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade
by: Yang Q, et al.
Published: (2020-06-01)

Neoadjuvant Anlotinib and chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced esophageal squamous cell carcinoma: Short-term results of an open-label, randomized, phase II trial
by: Ying-Jian Wang, et al.
Published: (2022-08-01)

Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma
by: Shenglong Li, et al.
Published: (2021-05-01)

Extraosseous Ewing Sarcoma in a Pelvic Region: A Case Report
by: Sushma Gurung, et al.
Published: (2022-07-01)

Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial
by: Shuangshuang Zhao, et al.
Published: (2024-01-01)

Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma
by: Jiuhui Xu, et al.
Published: (2023-06-01)

Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma
by: Emmy D. G. Fleuren, et al.
Published: (2023-03-01)

Anlotinib helps alleviate radiation pneumonitis: A case report
by: Jiazhen Chen, et al.
Published: (2021-12-01)

Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study
by: Xiaofeng Chen, et al.
Published: (2022-05-01)

Case report: Primary intracranial EWs/PNET in adults: Clinical experience and literature review
by: Xianwen Hu, et al.
Published: (2022-10-01)

Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trialResearch in context
by: Bushu Xu, et al.
Published: (2023-10-01)

Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trialResearch in context
by: Yan Liang, et al.
Published: (2024-05-01)

Anlotinib for the Treatment of Multiple Recurrent Lumbar and Sacral Cord Hemangioblastomas: A Case Report
by: Nan Jin, et al.
Published: (2022-04-01)

Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature
by: Yishi Zhang, et al.
Published: (2023-05-01)

The Role of Tyrosine Kinases as a Critical Prognostic Parameter and Its Targeted Therapies in Ewing Sarcoma
by: Wook Jin
Published: (2020-07-01)

Real-World Data on Cabozantinib in Advanced Osteosarcoma and Ewing Sarcoma Patients: A Study from the Hellenic Group of Sarcoma and Rare Cancers
by: Stefania Kokkali, et al.
Published: (2023-01-01)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
by: Liu Z, et al.
Published: (2021-02-01)

Anlotinib for Recurrent or Metastatic Primary Malignant Bone Tumor: A Multicenter, Single-Arm Trial
by: Lina Tang, et al.
Published: (2022-05-01)

Monophasic Synovial Sarcoma in the Elbow Misclassified but Successfully Treated as Ewing’s Sarcoma with Chemotherapy
by: Madariaga MC, et al.
Published: (2021-11-01)

Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer
by: Wenbo Qi, et al.
Published: (2023-01-01)

Neoadjuvant Chemotherapy with Ifosfamide, Cisplatin, Adriamycin and Mitomycin (IMAP) for High risk Adult Soft Tissue Sarcomas
by: Mohammad Ali Mohagheghi, et al.
Published: (2009-04-01)

Neoadjuvant Chemotherapy with Ifosfamide, Cisplatin, Adriamycin and Mitomycin (IMAP) for High risk Adult Soft Tissue Sarcomas
by: Mohagheghi Mohammad Ali, et al.
Published: (2009-05-01)

A case of complete resection of prostate stromal sarcoma after neoadjuvant chemotherapy
by: Naoto Hodotsuka, et al.
Published: (2023-07-01)

Sarcoma of the Ewing Family in Pregnancy: A Case Report of Intrauterine Fetal Death after Induction of Chemotherapy
by: S. Schur, et al.
Published: (2012-11-01)

Response to chemotherapy combined with anlotinib plus anlotinib maintenance in intra-abdominal desmoplastic small round cell tumors (IADSRCT): a case report and literature review
by: Ke Cheng, et al.
Published: (2022-08-01)

Targeted Therapy for EWS-FLI1 in Ewing Sarcoma
by: Helong Gong, et al.
Published: (2023-08-01)

Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study
by: Zhiyong Liu, et al.
Published: (2021-11-01)

Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial
by: Jianhui Ma, et al.
Published: (2020-05-01)

One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma
by: Guillermo Flores, et al.
Published: (2021-12-01)

Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China
by: Lu Xie, et al.
Published: (2018-04-01)

Anlotinib combined with radiotherapy and chemotherapy for recurrent pelvic osteosarcoma treatment: a case report and literature review
by: Qian Chen, et al.
Published: (2023-12-01)